The application of albumin-bound paclitaxel in neoadjuvant chemotherapy for breast cancer

Abstract

Objective To assess the efficacy and adverse reactions of albumin-bound paclitaxel combined with epirubicin and cyclophosphamide in neoadjuvant chemotherapy for patients with breast cancer. Methods 18 patients with breast cancer received neoadjuvant chemotherapy with albuminbound paclitaxel combined with epirubicin and cyclophosphamide for four cycles, and then underwent surgery. The efficay and adverse reactions were assessed. Results The pCR rate was 38.9% and the total effective rate ( cCR puls cPR ) was 88.9%. The major adverse reactions which all the patients could tolerate included bone marrow suppression, gastrointestinal tract reaction, and sensory neurotoxicity. No allergic response occurred. Conclusions The neoadjuvant chemotherapy with albumin-bound paclitaxel combined with epirubicin and cyclophosphamide for breast cancer is significantly effective, and has fewer adverse reactions and a good tolerance. Key words: Breast cancer; Neoadjuvant chemotherapy; Albumin-bound paclitaxel